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ABSTRACT
Background: Li–Fraumeni syndrome greatly increases
the risk of developing several types of cancer and is
usually caused by TP53 germline mutations. Predictive
testing of at-risk family members is only offered after a
complex genetic counselling process. Recently the clinical
implementation of array comparative genomic hybridisa-
tion (CGH) has revolutionised the diagnosis of patients
with syndromic or non-syndromic mental retardation and
has evolved to a routinely performed high resolution
whole genome scan.
Methods and results: When using array CGH to identify
the cause for mental retardation in a 7-year-old child we
found a submicroscopic de novo deletion of chromosome
17p13.1, which includes several genes likely to be
causative for her phenotype, and also of TP53.
Conclusion: Thus, array CGH resulted in an unintended
predictive diagnosis of an increased tumour susceptibility
as observed in Li–Fraumeni syndrome.
The list of well defined inherited cancer predis-
position syndromes, which can be attributed to a
hereditary susceptibility and have far reaching
implications for all family members, is steadily
growing. Many of these syndromes are caused by
germline alterations in a tumour suppressor gene.
Usually one functional copy of a tumour suppres-
sor gene is sufficient to exert the function.
However, inactivation of both alleles by mutation
or deletion can result in uncontrolled proliferation
and may therefore contribute to tumorigenesis.
Hence, individuals who have already one dysfunc-
tional tumour suppressor gene copy in all somatic
cells due to a germline mutation may have such an
increased tumour risk whenever the function of
the second copy is compromised in a cell. This
mechanism is usually referred to as Knudson’s
‘‘two-hit hypothesis’’.
1
In familial cancer syndromes the identification
of at-risk family members by predictive testing is
often recommended as enhanced surveillance for
early diagnosis and prevention of disease is a
critical part of primary care. Due to the extensive
consequences of such predictive testing it is usually
only offered after a complex genetic counselling
process. Sophisticated surveillance guidelines with
proven benefit were developed for several cancer
prone syndromes such as Lynch syndrome (heredi-
tary non-polyposis colon cancer (HNPCC)),
2 her-
editary breast and ovarian cancer due to mutations
in BRCA1 or BRCA2,
3 or for hereditary childhood
tumours such as retinoblastoma.
45
Array comparative genomic hybridisation
(CGH) has evolved to a standard application in
clinical genetics, especially in individuals with
syndromic or non-syndromic mental retardation.
As a consequence high resolution scans of entire
genomes for small gains and losses anywhere in the
genome are now conducted routinely. However,
the commonly applied execution of array CGH
bears the risk that deletions of genes involved in
hereditary cancer syndromes, especially tumour
suppressor genes, may also be identified, which
would then result in an unintended predictive
diagnosis of a cancer prone syndrome. Here we
report such a case in which we identified a
submicroscopic de novo deletion of chromosome
17p13.1, which included among other genes the
tumour suppressor TP53 gene. This scenario
represents new challenges for both clinical oncol-
ogists and genetic counsellors.
CASE REPORT
The proband was born at 42 weeks by sponta-
neous vaginal delivery following an uncomplicated
pregnancy; the Apgar score was 7/9/10. Birth
weight was 4180 g (.90th centile), length was
52 cm (75th centile), and the head circumference
(OFC) was 37 cm (90th centile).
Examinations at 4 and 5 months revealed a
psychomotor retardation with a generalised muscle
hypotonia. Dysmorphic features included a broad
and low set nasal bridge, a short philtrum and a
bifid uvula. The child could not establish visual
contact. Brain magnetic resonance imaging (MRI)
showed the presence of an enlarged fourth
ventricle, hypoplasia of the cerebellar vermis and
corpus callosum, anomalies usually classified as
incomplete manifestation of a Dandy–Walker
malformation or Dandy–Walker variant. Within
the first year short episodes of myoclonic seizures
occurred, which could be prevented by adminis-
tration of valproic acid and lamotrigine.
At 18 months of age she was able to sit. A severe
bilateral visual impairment and a high myopia of
212 D were diagnosed.
At 7 years of age she was able to walk without
support but with ataxic movements. She spoke a
few words. At this age the patient was presented
to our counselling service. In order to clarify the
cause of her impairment we obtained informed
consent from the parents to perform cytogenetic
analysis and high resolution array CGH.
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Cytogenetic analysis
Chromosome banding analyses of the proposita and her parents
were done according to standard protocols.
Array CGH
Array CGH was carried out using a whole genome oligonucleo-
tide microarray platform (Human Genome CGH 44B
Microarray Kit; Agilent Technologies, Santa Clara, California,
USA). This array consists of approximately 43 000 60-mer
oligonucleotide probes with a spatial resolution of 43 kb.
Samples were labelled with the Bioprime Array CGH Genomic
Labeling System (Invitrogen, Carlsberg, California, USA)
according to the manufacturer’s instructions. Further steps
were performed according to the manufacturer’s protocol
(version 6.0). Slides were scanned using a microarray scanner
(G2505B) and images were analysed using CGH Analytics
software 3.4.40 (both from Agilent Technologies) with the
statistical algorithm ADM-2, sensitivity threshold was 6.0. At
least three consecutive clones had to be aberrant to be identified
as significant change.
Fluorescence in situ hybridisation (FISH)
FISH was performed with a commercially available probe for
the TP53-region (LSI p53 Abbott/Vysis) according to the
manufacturer’s instructions.
Quantitative real-time polymerase chain reaction (qPCR)
As previously described, qPCR was performed in order to verify
the results from array CGH and to narrow down the breakpoint
region.
6 After narrowing down the breakpoint region to about
10 kb, we conducted PCR with primers from both sides. The
junction fragment was subsequently sequenced and compared
with the genomic sequence.
Sequencing
RNA was isolated from peripheral blood using the PAXgene
blood RNA system according to the manufacturer’s protocols
(PreAnalytiX). For cDNA synthesis we used the Omniscript RT
Kit (Qiagen) with oligo dT primers. Monoallelic expression of
GUCY2D was determined by sequencing a single nucleotide
polymorphism (SNP) (rs2816) from the 39UTR of GUCY2D in
both genomic DNA and cDNA.
Sequencing was performed by cycle sequencing using the ABI
BigDye Terminator Cycle Sequencing Kit according to the
supplier’s protocol and was analysed on an ABI3100 genetic
analyser (both ABI).
RESULTS AND DISCUSSION
Standard banding analysis of the proposita showed a normal
female karyotype (46,XX). In a next step we performed array
CGH, which revealed a small deletion in chromosome 17p13.1
(fig 1). When analysing the DNA of the parents and their
daughter by real-time PCR we identified this deletion only
when using the daughter’s but not the parental DNA. Provided
that none of the parents has a mosaic constellation the deletion
most likely occurred de novo. Furthermore, we applied a
commercially available TP53-specific probe to metaphase
spreads of the proposita, which confirmed the deletion (fig 2).
In addition, we determined the deletion size and the localisation
of the breakpoints by sequencing (fig 3). In summary, the exact
size of the deletion is 774 kb and contains 47 genes according to
current database entries (Ensemble release 50; www.ensembl.
org).
Several of the deleted genes can presumably be related to
some of the patient’s phenotypic features. For example, loss of
the KCNAB3 potassium channel gene is likely to be involved in
the occurrence of the patient’s seizures. Furthermore, the
deletion includes several neurotransmitter genes and kinases,
which may represent a contributing factor to the mental
retardation. A prime example for phenotype–genotype correla-
tion is the GUCY2D gene, which was disrupted from the cis-
regulatory elements by the breakpoint. We verified monoallelic
expression by sequencing an SNP (rs2816) within GUCY2D in
both genomic DNA and cDNA. This resulted in cone–rod
dystrophy 6 (CORD6; OMIM 601777), a diagnosis which was
indeed confirmed by our ophthalmologists and explains our
patient’s severely impaired vision.
However, we also identified a loss of the TP53 gene within
the deleted region. TP53 regulates the cell cycle and functions as
a tumour suppressor involved in preventing cancer. As such,
TP53 has been designated as the ‘‘guardian of the genome’’.
7 In
fact, the TP53 gene is the most commonly mutated gene in
human cancer.
8 The overall lifetime risk of cancer in patients
with TP53 germline mutations is in the range of 80–90%, with a
risk as high as 40% within the first two decades of life.
9
This condition was named Li–Fraumeni syndrome after the
physicians who first recognised it.
10 The classical definition of
the Li–Fraumeni syndrome is based on the following three
parameters: (1) a proband with a sarcoma diagnosed before the
age of 45; (2) a first degree relative with cancer before the age of
45; and (3) another first or second degree relative with either a
sarcoma diagnosed at any age or any cancer diagnosed under the
age of 45.
11 Although sarcomas are quite frequently observed in
Li–Fraumeni syndrome, a broad range of other tumours may
occur including breast cancer, bone cancer, brain tumours, lung
cancer, laryngeal cancer, leukaemia, adrenal cortical neoplasia,
and others. Furthermore, more relaxed criteria were released for
variations of a Li–Fraumeni-like syndrome.
12 13
In the absence of a positive family history and without any
tumour our patient does not formally fulfil the criteria for Li–
Fraumeni or Li–Fraumeni-like syndrome. However, the com-
plete loss of one copy of the TP53 gene in our patient should
result in a similar if not identical tumour risk as affected
members of Li–Fraumeni syndrome families according to the
aforementioned two-hit hypothesis. Therefore, we assess that
our patient has a greatly increased tumour risk with all the
unusual characteristics of the Li–Fraumeni syndrome, including
that several kinds of cancers may be involved, that cancer may
strike at a young age, and that cancer may strike several times
throughout the patient’s life.
As mentioned before there are cancer prone syndromes in
which clear guidelines for surveillance have been established and
their benefit has been proven. In contrast, TP53 germline
mutations represent a special scenario, as the variable expres-
sivity and penetrance and the diversity of the tumour spectrum
render clinical surveillance and genetic testing a difficult task. As
a consequence there are no guidelines for patients with TP53
mutations and the benefit of any kind of surveillance has not
been proven yet.
41 4 Nevertheless, the American Society of
Clinical Oncology (ASCO) considers Li–Fraumeni syndrome to
be a syndrome for which predictive testing should be
considered, especially within research studies.
15
However, these considerations usually refer to an adult
individual who is able to give informed consent. In the case of
children, who are not able to give informed consent, predictive
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a multidisciplinary team should decide whether such a test for
a cancer predisposition syndrome, in which many tumours do
not manifest until later in life, is to the child’s benefit.
Therefore, the welfare of the child should always be the major
consideration.
5
In our case such careful considerations before testing had not
been possible. The patient’s situation is further complicated by
her severe mental retardation, as she may complain about
possible symptoms from a tumour growth only at an advanced
stage or even not at all, which poses an additional risk for a
delayed diagnosis. We informed the patient’s parents in
extensive genetic counselling sessions. Furthermore, we formed
a multidisciplinary team in order to discuss possible surveillance
options. At present this surveillance is confined to regular
Figure 1 The top panel illustrates the array comparative genomic hybridisation profile of chromosome 17 demonstrating a small deletion in
chromosome band 17p13.1. The lower panel depicts an enlargement of the deleted region. The exact localisation of the breakpoints was determined by
sequence analysis. The TP53 gene is almost at the centre of the deleted region. The GUCY2D gene is not included in the deleted region. However, the
cis-regulatory elements are deleted, which explains the monoallelic expression of the gene and as a consequence the patient’s cone–rod dystrophy 6.
Figure 2 Hybridisation of a commercially available TP53 specific probe
to metaphase spreads of the proposita, resulting in only one signal
confirming the deletion of the respective region.
Figure 3 Chromatogram showing the exact location of the breakpoints
and the resulting size of the deletion.
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abdomen.
As array CGH has evolved into a standard diagnostic tool for
a variety of conditions,
16 it is very likely that with the advancing
use of this technology similar deletions, or deletions of other
cancer prone syndromes, will be identified. In each case it will
place the physician or genetic counsellor in a special situation as
a risk evaluation for tumour development will have to be
offered, although this had not been requested initially by the
patient or her/his family. The growing risk of identifying
individuals with an increased lifetime risk for cancer by accident
will fuel the need for sophisticated risk stratification to achieve
a better prediction for the occurrence of possible tumour types
and the timing of cancer.
17
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